1,240
Participants
Start Date
April 30, 2008
Primary Completion Date
May 31, 2009
Study Completion Date
January 31, 2011
Dapagliflozin
tablet oral 2.5 mg total daily dose once daily 48 weeks (= 24 week randomised treatment period + 24 week study extension period I)
Dapagliflozin
Tablet oral 5 mg total daily dose once daily 48 weeks (= 24 week randomised treatment period + 24 week study extension period I)
Dapagliflozin
Tablet oral 10 mg total daily dose once daily 48 weeks (= 24 week randomised treatment period + 24 week study extension period I)
Placebo
Placebo
Dapagliflozin
tablet oral 2.5 total daily dose once daily 56 weeks (= 56 week study extension period II)
Dapagliflozin
tablet oral 10 mg total daily dose once daily 56 weeks (= 56 week study extension period II)patients that have been treated with 5 mg during the 24 week randomised treatment period and extension I period will during extension II period switched to 10 mg
Research Site, Fresno
Research Site, Greenbrae
Research Site, Roswell
Research Site, Chicago
Research Site, Springfield
Research Site, Indianapolis
Research Site, Omaha
Research Site, Philadelphia
Research Site, Corpus Christi
Research Site, Dallas
Research Site, Norfolk
Research Site, Richmond
Research Site, Tacoma
Research Site, Salzburg
Research Site, Vienna
Research Site, Pleven
Research Site, Rousse
Research Site, Sofia
Research Site, Varna
Research Site, Calgary
Research Site, Kelowna
Research Site, Langley
Research Site, Winnipeg
Research Site, Moncton
Research Site, Mount Pearl
Research Site, St. John's
Research Site, Halifax
Research Site, Etobicoke
Research Site, Kingston
Research Site, London
Research Site, Oakville
Research Site, Scarborough Village
Research Site, Thornhill
Research Site, Chicoutimi
Research Site, Longueuil
Research Site, Mirabel
Research Site, Sherbrooke
Research Site, Lahti
Research Site, Helsinki
Research Site, Joensuu
Research Site, Jyväskylä
Research Site, Kuopio
Research Site, Oulu
Research Site, Seinäjoki
Research Site, Turku
Research Site, Bad Oeynhausen
Research Site, Dortmund
Research Site, Dresden
Research Site, Essen
Research Site, Frankfurt
Research Site, Magdeburg
Research Site, Münster
Research Site, Riesa
Research Site, Wolmirstedt
Research Site, Csongrád
Research Site, Esztergom
Research Site, Győr
Research Site, Kaposvár
Research Site, Kecskemét
Research Site, Komárom
Research Site, Miskolc
Research Site, Székesfehérvár
Research Site, Veszprém
Research Site, Amersfoort
Research Site, Den Helder
Research Site, Leiden
Research Site, Rotterdam
Research Site, Brasov
Research Site, Tg Mures
Research Site, Bucharest
Research Site, Moscow
Research Site, Nizhny Novgorod
Research Site, Saint Petersburg
Research Site, Bratislava
Research Site, Dolný Kubín
Research Site, Košice
Research Site, Levice
Research Site, Lučenec
Research Site, Považská Bystrica
Research Site, Prešov
Research Site, Seville
Research Site, Sabadell (barcelona)
Research Site, Madrid
Research Site, Alicante
Research Site, Reading
Research Site, Aylesbury
Research Site, Ashford
Research Site, Birmingham
Research Site, Cardiff
Research Site, Liverpool
Research Site, Reading
Research Site, Swansea
Lead Sponsor
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
AstraZeneca
INDUSTRY